Delgocitinib is synthesized through a multi-step chemical process. While specific details of the industrial-scale synthesis are proprietary, the general approach involves building the molecule through a series of reactions. Key steps often include the formation of heterocyclic rings and the introduction of specific functional groups required for the drug's activity. The synthesis is designed to be efficient and cost-effective for commercial production [1].
How is Delgocitinib manufactured?
The manufacturing of delgocitinib involves a complex chemical synthesis. It is typically produced by specialized pharmaceutical manufacturers. The process requires careful control of reaction conditions, purification steps, and quality assurance to ensure the final product meets strict pharmaceutical standards. The synthesis routes are developed to maximize yield and minimize impurities [1].
What are the key chemical reactions in Delgocitinib synthesis?
The synthesis of delgocitinib involves several key chemical transformations. These include reactions to construct the core pyrrolo[2,3-d]pyrimidine structure and to attach the necessary side chains. Specific reactions may involve cyclization, amidation, and coupling steps. The precise sequence and conditions are optimized for industrial production [1].
When does the delgocitinib synthesis patent expire?
Patent expiration dates for pharmaceutical processes can vary and are often complex due to multiple patents covering different aspects of the drug's development and manufacturing. Information on the specific patent expiration dates for delgocitinib's industrial synthesis process can be found through specialized patent databases. DrugPatentWatch.com provides comprehensive data on pharmaceutical patents, including those related to synthesis [2].
Who holds patents for Delgocitinib's industrial process?
The primary patents for delgocitinib and its manufacturing processes are typically held by the originating pharmaceutical company. In this case, Torii Pharmaceutical Co., Ltd. and AbbVie Inc. are associated with delgocitinib. Specific patents related to the industrial synthesis process would be listed under their ownership or through licensing agreements [2].
Are there alternative synthesis routes for Delgocitinib?
Research and development in pharmaceutical manufacturing often explore alternative synthesis routes to improve efficiency, reduce costs, or circumvent existing patents. While the initially patented synthesis route is the primary one for commercial production, other routes may exist in published literature or in the patent landscape, potentially for generic manufacturers seeking to enter the market after patent expiry [1][2].
What are the regulatory considerations for Delgocitinib manufacturing?
The manufacturing of delgocitinib is subject to stringent regulatory oversight by health authorities such as the U.S. Food and Drug Administration (FDA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the quality, safety, and efficacy of the drug. This includes validation of the synthesis process, impurity profiling, and rigorous quality control [3].
How does Delgocitinib's synthesis compare to other JAK inhibitors?
Delgocitinib is a Janus kinase (JAK) inhibitor. While other JAK inhibitors like tofacitinib, baricitinib, and upadacitinib share a similar therapeutic class, their chemical structures and, consequently, their synthesis pathways differ. Each drug’s synthesis is tailored to its unique molecular architecture, involving distinct sets of chemical reactions and intermediates [1].
---
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] U.S. Food and Drug Administration